It's difficult to call a stock with an EV/EBITDA ratio in the 20's and
more than a dozen active sell-side analysts "undiscovered", but I'm
surprised at the relative level of chatter about Volcano (VOLC) in comparison to names like Intuitive Surgical (ISRG), MAKO Surgical (MAKO), or Abiomed (ABMD).
While Volcano arguably suffers from the fact that its addressed markets
have been around quite a bit longer, I believe growth-oriented
investors ought to take another look at some of the possibilities of
Volcano finding a new level of market acceptance and growth in the
coming years.
Read the full Seeking Alpha article here:
A Greater Focus On Outcomes Could Be Explosive For Volcano
No comments:
Post a Comment